Clinical Trials Logo

Juvenile Absence Epilepsy clinical trials

View clinical trials related to Juvenile Absence Epilepsy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06315322 Not yet recruiting - Clinical trials for Childhood Absence Epilepsy

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Start date: April 2024
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.

NCT ID: NCT06153186 Terminated - Clinical trials for Childhood Absence Epilepsy

Flunarizine for Treatment Resistant Absence Epilepsy

Start date: September 20, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single-centre study to evaluate the clinical efficacy, safety and tolerability of Flunarizine administered as adjunctive treatment in participants diagnosed with treatment resistant absence epilepsy. The study goal is to see how efficient and safe flunarizine is at decreasing the frequency of absence seizures in children with treatment-resistant refractory epilepsy at doses of 5mg and 10mg once daily.

NCT ID: NCT05109234 Enrolling by invitation - Clinical trials for Childhood Absence Epilepsy

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Start date: March 30, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

NCT ID: NCT04666610 Recruiting - Clinical trials for Childhood Absence Epilepsy

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

EXPAND
Start date: July 29, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).